Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 63Cyclophosphamide 57fludarabine phosphate 40fludarabine 37ibrutinib 28Lenalidomide 26Bendamustine Hydrochloride 26Filgrastim 20venetoclax 19obinutuzumab 17Bortezomib 17Peripheral Blood Stem Cell Transplantation 15Etoposide 12Biopsy 12Tacrolimus 11Specimen Handling 11Melphalan 11Interleukin-2 10tanespimycin 9Radiotherapy 9Cytarabine 9aldesleukin 8Whole-Body Irradiation 8Magnetic Resonance Spectroscopy 8idelalisib 7Vorinostat 7Paclitaxel 7Mycophenolic Acid 7Ipilimumab 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphocytic, Chronic, B-Cell × Erythromycin × Clear all
NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡